- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BYD Atto 2: China-Update bringt 501 km Reichweite | 17 | ElektroQuatsch | ||
| Mi | Attovia auf Morgan Stanley Konferenz: Pipeline-Fortschritte nach Börsengang | 1 | Investing.com Deutsch | ||
| 11.09. | BYD's Most Powerful ATTO 3 Lands In Malaysia | 27 | BusinessToday | ||
| 02.09. | Attovia flags ATTO-1310 itch data, Phase 1b readout Q4 | 1 | The Market Online Canada | ||
| 02.09. | Attovia Therapeutics, Inc. GAAP EPS of -$4.88 misses by $4.25, revenue of $0.45M | 1 | Seeking Alpha | ||
| ATTOVIA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.09. | Attovia Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.09. | Attovia Therapeutics, Inc.: Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | 283 | GlobeNewswire (Europe) | ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic... ► Artikel lesen | |
| 31.08. | Attovia: Positive Studiendaten zu Juckreiz-Medikament beflügeln Analysten | 1 | Investing.com Deutsch | ||
| 31.08. | RBC startet Coverage für Attovia mit "Outperform" und sieht über 115 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 31.08. | RBC initiates Attovia stock with Outperform on IL-31 drug potential | 1 | Investing.com | ||
| 31.08. | Morgan Stanley startet Coverage für Attovia mit "Overweight" | 1 | Investing.com Deutsch | ||
| 31.08. | Morgan Stanley initiates Attovia stock with overweight rating | 1 | Investing.com | ||
| 16.08. | BYD Atto 3 Evo im Test: Viel Auto für den Preis | 4.267 | electrive.net | Von außen ändert sich fast nichts, unter dem Blech aber praktisch alles: BYD hat beim Atto 3 Evo genau die beiden Schwächen behoben, die den Vorgänger ausgebremst haben. Statt mit nur 110 kW lädt er... ► Artikel lesen | |
| 06.08. | Attovia Therapeutics, Inc.: Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 359 | GlobeNewswire (Europe) | SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for... ► Artikel lesen | |
| 06.08. | Qiming Venture Partners: Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq | 492 | PR Newswire | SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq... ► Artikel lesen | |
| 05.08. | Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders | 2 | MedCity News | ||
| 05.08. | Attovia adds to biotech IPO momentum with $289M offering | 1 | BioPharma Dive | ||
| 05.08. | Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected | 2 | Renaissance Capital | ||
| 05.08. | Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO | 1 | FierceBiotech | ||
| 05.08. | Attovia Therapeutics prices upsized IPO at $17 per share, targets $289M raise | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
ATTOVIA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,14 % bei einem Aktienkurs von 22,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATTOVIA THERAPEUTICS INC finden Sie auf Wallstreet Online.